latest update:
[TrialBase DB]

trial summary · NCT07350863

U69-CART-Cells For R/R T-ALL

A Phase I, Single-Arm, Open-Label Clinical Study to Evaluate the Safety and Efficacy of U69 in Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL/LBL)

Trial record from the TrialBase DB dataset, status RECRUITING, condition Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma, sponsored by The First Affiliated Hospital of Soochow University. Facts below are exported values from the current release, not inferred or edited prose.

registry NCT07350863phase PHASE1enrollment 12start 2026-10-25

Summary

The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.

Overall Introduction This single-arm, open-label clinical trial aims to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of CXCR4-enabled CCR9 chimeric antigen receptor T-cell injection (CXCR4 CCR9 CAR-T) in patients with relapsed or refractory T-lymphoblastic leukemia/lymphoma (r/r T-ALL/LBL). Additionally, the study seeks to preliminarily assess the efficacy of CXCR4 CCR9 CAR-T cells and explore the appropriate dosage and administration schedule for subsequent Phase II clinical trials. A dose escalation study following the 3+3 design was implemented across three dose cohorts, with each cohort planned to enroll 3 to 6 patients, totaling 9 to 18 participants. Following cell infusion, subjects underwent safety and efficacy follow-up, which continued until 2 years post-infusion, subject withdrawal, or study termination-whichever occurred first. For subjects with available follow-up information after study completion or early termination, long-term follow-up-including long-term safety monitoring-was conducted for up to 15 years.

Source record: https://clinicaltrials.gov/study/NCT07350863

Facts

registry idNCT07350863
primary registryclinicaltrials-gov
recruitment statusRECRUITING
phasePHASE1
study typeINTERVENTIONAL
lead conditionRelapsed/Refractory T-lymphoblastic Leukemia/Lymphoma
sponsorThe First Affiliated Hospital of Soochow University
sponsor classOTHER
enrollment12
start date2026-10-25
primary completion2026-12-15
completion2028-07-15
results postednot reported

Conditions

  • Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma

Interventions

  • CXCR4 CCR9 CAR-T

Countries

  • China

Intervention types: DRUG

Work with this record